Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanine-rich DNA sequences are genomic regions characterized by a high density of guanine nucleotides, which are capable of folding into non-canonical four-stranded structures known as G-quadruplexes (G4s). These sequences are non-randomly distributed throughout the human genome, clustering in functional regions such as telomeres, ribosomal DNA, and the promoter regions of potent oncogenes like MYC, BCL2, and KRAS (Rhodes & Lipps, 2015, Nucleic Acids Res). Biologically, these structures act as regulatory elements that influence DNA replication, gene transcription, and telomere protection. In the context of disease, G-rich regions are frequently associated with cancer progression and neurodegenerative disorders, such as C9orf72-linked amyotrophic lateral sclerosis, where repeat expansions form toxic structures (DeJesus-Hernandez et al., 2011, Neuron). Therapeutic intervention typically involves small molecules that stabilize G-quadruplexes to inhibit oncogene expression or traditional alkylating agents like cisplatin that bind guanine to cause lethal DNA damage (Dasari & Bernard Tchounwou, 2014, Eur J Pharmacol). However, targeting these sites presents significant challenges regarding selectivity and the risk of systemic genotoxicity.
Drugs targeting these regions typically act by stabilizing non-canonical structures like G-quadruplexes to inhibit transcription and replication, or by forming covalent adducts and cross-links with guanine bases to induce DNA damage and apoptosis (Dasari & Bernard Tchounwou, 2014; Rhodes & Lipps, 2015).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanine-rich DNA sequences (G-rich DNA).